Insilico expands Tenacia CNS collaboration in $94.75M deal

CURRENT FULL VERSION: Insilico Medicine and Tenacia Biotechnology have expanded their CNS drug discovery partnership in a deal worth up to $94.75 million, extending a relationship that began in March 2025. The new agreement adds a second AI-driven program aimed at generating an additional blood-brain barrier-aware candidate for difficult neurological diseases, with Insilico eligible for near-term and milestone payments as the work advances toward the preclinical candidate stage. (barchart.com)

The update matters because it moves the collaboration beyond a single exploratory research pact and into a broader platform-style relationship. In the original March 3, 2025 announcement, the companies said they would combine Insilico’s Pharma.AI drug discovery engine with Tenacia’s scientific and clinical expertise in nervous system disorders to discover novel CNS small molecules from scratch. That first program focused on blood-brain barrier-penetrant inhibitors, one of the most persistent bottlenecks in CNS drug development. (eurekalert.org)

Under the expanded March 26, 2026 agreement, the partners said the initial program has progressed smoothly, prompting them to launch a second effort against the same target but with differentiated properties. Insilico framed that as evidence that generative AI can rapidly explore multiple molecular profiles around a difficult CNS biology problem, while Tenacia emphasized the value of combining its disease-area expertise and proprietary data with Insilico’s design platform. The companies did not disclose the target, specific indication, or economics beyond the deal’s total potential value and the mix of near-term and milestone payments. (barchart.com)

The announcement also fits a broader run of business development activity by Insilico since late 2025. According to the company’s PR Newswire release archive, Insilico announced an $888 million oncology collaboration with Servier on January 4, 2026, a near-$120 million cardiometabolic partnership with Qilu on January 27, 2026, multiple collaborations in CNS and autoimmune disease with CMS on February 10, 2026, and then this Tenacia expansion on March 26, 2026. On March 29, 2026, it also announced a global R&D collaboration with Lilly. Trade coverage described that Lilly alliance as a much larger multi-program deal worth up to about $2.75 billion, including $115 million upfront, with Lilly receiving exclusive global rights to develop, manufacture, and commercialize Insilico preclinical oral candidates for select indications, plus additional R&D programs on Lilly-selected targets using Pharma.AI. Taken together, that suggests Insilico is leaning hard into partnership revenue and external validation of its platform after listing on the Hong Kong Stock Exchange on December 30, 2025. That last point is an inference based on the timing and volume of deals, not a stated company strategy in the Tenacia release. (prnewswire.com; PharmaShots)

Direct outside commentary on this specific Tenacia expansion appears limited so far, but the companies’ own statements point to the commercial thesis. Insilico CEO Alex Zhavoronkov said launching a second program with differentiated attributes on the same target in a short time frame shows the “depth and flexibility” of generative AI in drug design, while Tenacia said progress in the first collaboration demonstrated the value of combining the two organizations’ expertise. Separately, Tenacia has been building out its CNS footprint through other regional partnerships, including a Greater China collaboration with Rapport Therapeutics announced in March 2026, underscoring that it is positioning itself as a neuroscience-focused development and commercialization partner. (barchart.com)

Why it matters: For veterinary professionals, the immediate impact is indirect, but the signal is relevant. Companion animal neurology faces many of the same translational constraints seen in human CNS drug development, especially around target selection, molecule optimization, safety, and central penetration. Insilico’s press materials explicitly say the company is extending Pharma.AI into veterinary medicine alongside human therapeutics, suggesting the same discovery infrastructure could eventually influence animal health pipelines as AI-first R&D models mature. More broadly, this deal is another indicator that biopharma companies are willing to pay meaningful sums for AI-enabled discovery in disease areas with high attrition and long timelines. The contrast between the relatively focused Tenacia expansion and the much larger Lilly collaboration also helps show the range of partnership formats now being built around AI discovery platforms, from target-specific CNS programs to multi-asset, multi-therapeutic-area alliances with global commercialization rights attached. (barchart.com; PharmaShots))

There’s also a practical takeaway for clinicians and industry watchers: the value of these deals still depends on whether they yield candidates that survive preclinical and clinical testing. Insilico has pointed to internal benchmarks showing faster design timelines than traditional discovery, and it has advanced multiple internally discovered assets, including the brain-penetrant NLRP3 inhibitor ISM8969, which received FDA IND clearance on January 23, 2026. But the Tenacia collaboration remains at the discovery-to-preclinical stage, where many programs still fail. At the same time, larger alliances such as Lilly’s will test whether Insilico can scale from generating individual candidates to supporting several parallel programs across therapeutic areas while meeting the expectations that come with upfront cash, milestone structures, and downstream royalty economics. (eurekalert.org; PharmaShots)

What to watch: The next milestones will be whether the partners disclose the target or indication, nominate a preclinical candidate from either program, and show that AI-designed CNS molecules can move from computational promise into reproducible development progress. If Insilico continues stacking deals and converting them into named assets, that will strengthen the case that AI discovery platforms are becoming a durable part of the biopharma business model, including in adjacent areas such as animal health. It will also be worth watching whether the company can execute simultaneously on smaller specialized collaborations like Tenacia and on large multi-program partnerships like Lilly, where the commercial stakes and operational demands are much higher. (barchart.com; PharmaShots)